- Home
- ALXO vs LSTA Comparison
ALXO vs LSTA Comparison
Compare ALXO & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- LSTA
- Stock Information
- Founded
- ALXO 2015
- LSTA 1980
- Country
- ALXO United States
- LSTA United States
- Employees
- ALXO N/A
- LSTA N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- ALXO Health Care
- LSTA Health Care
- Exchange
- ALXO Nasdaq
- LSTA Nasdaq
- Market Cap
- ALXO 24.0M
- LSTA 20.9M
- IPO Year
- ALXO 2020
- LSTA N/A
- Fundamental
- Price
- ALXO $0.41
- LSTA $2.80
- Analyst Decision
- ALXO Strong Buy
- LSTA Strong Buy
- Analyst Count
- ALXO 6
- LSTA 1
- Target Price
- ALXO $3.30
- LSTA $15.00
- AVG Volume (30 Days)
- ALXO 613.7K
- LSTA 14.5K
- Earning Date
- ALXO 08-07-2025
- LSTA 08-11-2025
- Dividend Yield
- ALXO N/A
- LSTA N/A
- EPS Growth
- ALXO N/A
- LSTA N/A
- EPS
- ALXO N/A
- LSTA N/A
- Revenue
- ALXO N/A
- LSTA $1,000,000.00
- Revenue This Year
- ALXO N/A
- LSTA N/A
- Revenue Next Year
- ALXO N/A
- LSTA N/A
- P/E Ratio
- ALXO N/A
- LSTA N/A
- Revenue Growth
- ALXO N/A
- LSTA N/A
- 52 Week Low
- ALXO $0.40
- LSTA $1.87
- 52 Week High
- ALXO $8.78
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- ALXO 40.22
- LSTA 59.64
- Support Level
- ALXO $0.45
- LSTA $2.36
- Resistance Level
- ALXO $0.53
- LSTA $2.69
- Average True Range (ATR)
- ALXO 0.05
- LSTA 0.22
- MACD
- ALXO -0.01
- LSTA 0.02
- Stochastic Oscillator
- ALXO 4.98
- LSTA 62.50
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.